Chair
Member
Audit Committee Position

Jerry McLaughlin

Mr. McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded and currently serves as Chairman and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start-up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin also serves on the board of directors of DataStream Medical Imaging Systems, Inc., a private company in the medical imaging software industry.

Chair

Jay Birnbaum

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio. Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Member

Phillipe Weigerstorfer

Mr. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma's board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. In 1999, Weigerstorfer joined Galencia Ltd's executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market.

Member

Audit Committee Charter

Download
Compensation Committee Position

Jerry McLaughlin

Mr. McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded and currently serves as Chairman and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start-up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin also serves on the board of directors of DataStream Medical Imaging Systems, Inc., a private company in the medical imaging software industry.

Chair

Jay Birnbaum

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio. Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Phillipe Weigerstorfer

Mr. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma's board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. In 1999, Weigerstorfer joined Galencia Ltd's executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market.

Chair

Jay Birnbaum

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio. Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Member

Nominating and Corporate Governance Committee Charter

Download

Jerry McLaughlin

Mr. McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded and currently serves as Chairman and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start-up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin also serves on the board of directors of DataStream Medical Imaging Systems, Inc., a private company in the medical imaging software industry.

Jay Birnbaum

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio. Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Phillipe Weigerstorfer

Mr. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma's board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. In 1999, Weigerstorfer joined Galencia Ltd's executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market.

Jerry McLaughlin

Mr. McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded and currently serves as Chairman and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start-up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin also serves on the board of directors of DataStream Medical Imaging Systems, Inc., a private company in the medical imaging software industry.

Jay Birnbaum

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio. Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Phillipe Weigerstorfer

Mr. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma's board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. In 1999, Weigerstorfer joined Galencia Ltd's executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market.

Jay Birnbaum

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio. Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.